Entera Bio Announces Publication of Phase 2 Hypoparathyroidism Study in the Journal of Bone and Mineral Research
February 25, 2021 08:30 ET
|
Entera Bio Ltd.
‒ EB612 When Added to Standard of Care Led to a Statistically Significant Decrease in Supplemental Calcium Usage – ‒ Oral Human Parathyroid Hormone (1-34) Has the Potential to Have a Major Impact on...
Entera Bio Initiates New Research Program For Oral GLP-2
February 08, 2021 08:30 ET
|
Entera Bio Ltd.
‒ Program Leverages Entera’s Platform for Potential Development of Oral GLP-2 Analogs for Gastrointestinal and Other Indications ‒‒ GLP-2 Analogs Currently Administered Via Daily Injection to Treat...
Entera Bio Issues Letter to Shareholders
January 11, 2021 08:30 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today issued a Letter to...
Entera Bio Announces FDA Approval of IND Application for EB613 – an Oral Human Parathyroid Hormone (1-34) for the Treatment of Osteoporosis
December 10, 2020 08:30 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Israel, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today that the...
Entera Bio Appoints Spiros Jamas as Chief Executive Officer
November 30, 2020 16:05 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today that its...
Entera Bio Ltd Announces Third Quarter 2020 Financial Results and Provides Clinical Update
November 19, 2020 06:30 ET
|
Entera Bio Ltd.
‒ Completed Enrollment in Phase 2 Clinical Trial of EB613, Positioned as the First Potential Oral Bone Building Product to Treat Osteoporosis ‒‒ Positive Interim 6-Month Bone Mineral Density (BMD)...
Entera Bio to Report Third Quarter 2020 Business and Financial Results on November 19, 2020
November 13, 2020 07:30 ET
|
Entera Bio Ltd.
BOSTON JERUSALEM, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and...
Entera Bio Ltd Announces Completion of Enrollment In Phase 2 Clinical Trial of Eb613 In Osteoporosis
November 09, 2020 08:30 ET
|
Entera Bio Ltd.
‒ Company Expects to Report Interim 3 Month Biomarker Data for All Enrolled Patients in Q1:21 with Final Bone Mineral Density, or BMD, Data Expected in Q2:21 ‒ ‒ Results Expected Are Expected to...
Entera Bio to Present at the H.C. Wainwright 6th Annual Israel Conference
November 02, 2020 16:05 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its...
Entera Bio to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 10, 2020 08:30 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its...